What is the primary purpose of this 10-Q/A filing?

This filing is an amendment to Vertex Pharmaceuticals Inc.'s Quarterly Report (10-Q). It signifies that the original filing submitted for the period ending March 30, 1996, contained errors or omissions that needed to be corrected. The amendment provides the updated and accurate financial information.

Why is the fact that this is an amendment important for investors?

Amendments can signal potential issues with financial reporting accuracy, accounting practices, or previously disclosed information. For investors, it necessitates a deeper review to understand the nature and impact of the corrections. It's important to compare the amended filing with the original to grasp the extent of the changes and ensure an accurate understanding of the company's financial performance and position.

Where can I find the specific financial details and reasons for the amendment?

The provided excerpt is a directory listing and does not contain the detailed financial statements or management's discussion and analysis. To find the specific financial details and the reasons for the amendment, investors must access and review the full amended 10-Q filing (document number 000095013596003171) from the SEC's EDGAR database.

What is the significance of the filing date (July 22, 1996) and period end date (March 30, 1996)?

The period ending March 30, 1996, indicates the financial quarter that the report covers. The filing date of July 22, 1996, along with it being an amendment (10-Q/A), suggests that the company took approximately four months from the period end to file the original report and then further time to amend it. This timeline, especially for an amendment, might warrant attention regarding the internal processes for financial reporting and control.

VRTX 10-Q Filed Jul 23, 1996

Summary

This filing is an amendment to Vertex Pharmaceuticals Inc.'s Quarterly Report for the period ending March 30, 1996, filed on July 22, 1996. As this is an amendment, it suggests that there were initial inaccuracies or omissions in the original filing that are being corrected. Investors should pay close attention to the nature of these amendments, as they could indicate significant accounting issues, changes in financial reporting, or adjustments to previously disclosed information. The specific details of the amendments are not provided in the provided excerpt, but the fact of an amendment itself warrants further investigation into the reasons behind it. It's crucial for investors to review the full amended filing to understand any impact on the company's financial position, results of operations, and disclosures. Given the early stage of Vertex Pharmaceuticals (filed in 1996), understanding any amendments is critical for assessing the company's foundational financial health and reporting integrity. Investors should look for clarity on the reasons for the amendment, the specific data points changed, and whether these changes materially alter the previously presented financial picture. This filing should be viewed in conjunction with the original 10-Q to fully grasp the updated financial narrative.

Key Highlights

1The filing is an Amendment (10-Q/A) to Vertex Pharmaceuticals Inc.'s Quarterly Report.
2The report covers the period ending March 30, 1996.
3The amendment was filed on July 22, 1996, indicating a delay or correction to the original filing.
4The excerpt provided is a directory listing, not the full financial statements or management discussion.
5Investors must consult the full amended filing for specific details on the changes made.
6The nature of the amendment (e.g., accounting error, disclosure update) is crucial for investor analysis.
7This filing represents historical financial information from 1996.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report (Amendment) for Q1 Ended Mar 31, 1996

Summary

Key Highlights

Frequently Asked Questions